As shown in Fig. 5, a comparable expression of the receptor was observed (Fig. 6A) and ATF-SAP dose-dependent biological activity was in line with previous results (Fig. 6B), further supporting the use of grade 2 bladder cancer cell lines as suitable in vivo models to test the chimera pharmacological efficacy. The gene discussed is PLAU; the disease is urinary bladder cancer.